Acclarent
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$25.0m | Series B | ||
$35.0m | Series C | ||
$26.0m | Late VC | ||
$785m Valuation: $785m | Acquisition | ||
* | $275m | Acquisition | |
Total Funding | €78.2m |
Related Content
Recent News about Acclarent
EditAcclarent, a subsidiary of Johnson & Johnson Medical Devices Companies, specializes in developing minimally invasive ear, nose, and throat (ENT) solutions. The company primarily serves healthcare providers, including hospitals and specialized ENT clinics, by offering advanced medical devices designed to improve patient outcomes and streamline surgical procedures. Operating within the medical device industry, Acclarent focuses on innovation and the integration of cutting-edge technology to address common ENT issues such as chronic sinusitis and Eustachian tube dysfunction. The business model revolves around the research, development, and commercialization of these specialized devices, generating revenue through the sale of its products to medical institutions and practitioners. Acclarent leverages Johnson & Johnson's extensive distribution network and expertise in medical technology to maintain a competitive edge in the market.
Keywords: ENT solutions, minimally invasive, medical devices, chronic sinusitis, Eustachian tube, healthcare providers, innovation, patient outcomes, surgical procedures, Johnson & Johnson.